Dec 12 (Reuters) - Editas Medicine Inc :
* ANNOUNCES STRATEGIC TRANSITION TO IN VIVO GENE EDITING COMPANY WITH INTENT TO ACHIEVE HUMAN PROOF OF CONCEPT IN APPROXIMATELY TWO YEARS
* INITIATING COST SAVINGS MEASURES AND REDUCTION IN HEADCOUNT TO ALIGN WORKFORCE
* WILL ELIMINATE APPROXIMATELY 65% OF ITS WORKFORCE OVER NEXT SIX MONTHS
* INTENDS TO SHARE PRE-CLINICAL DATA AND FURTHER DEVELOPMENT TIMELINES FROM PROGRAMS IN Q1 OF 2025
* JESSICA HOPFIELD, HAS BEEN NAMED CHAIR OF BOARD, EFFECTIVE DECEMBER 31
((Reuters.Briefs@thomsonreuters.com;;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.